NASDAQ:PSTI Pluristem Therapeutics (PSTI) Stock Price, News & Analysis → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Free PSTI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$1.00▼$1.5852-Week Range N/AVolume2,128 shsAverage Volume715,259 shsMarket Capitalization$32.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Pluristem Therapeutics alerts: Email Address Ad Stansberry ResearchThe "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. One Former Wall St. Trader Explains Why… About Pluristem Therapeutics Stock (NASDAQ:PSTI)Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.Read More Ad Stansberry ResearchThe "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. One Former Wall St. Trader Explains Why… PSTI Stock News HeadlinesAugust 18, 2023 | seekingalpha.comNBRVF Nabriva Therapeutics plcJuly 25, 2022 | finance.yahoo.comPluri CEO Issues Shareholder UpdateApril 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."July 25, 2022 | benzinga.comPluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional IndustriesJuly 25, 2022 | finance.yahoo.comPluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional IndustriesJuly 14, 2022 | finance.yahoo.comPluristem (PSTI) Phase III Study Misses Goal, Stock DownJuly 13, 2022 | finance.yahoo.comPluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture SurgeryJuly 13, 2022 | markets.businessinsider.comPluristem's Phase 3 Study Of PLX-PAD To Treat Muscle Injury Does Not Meet Primary GoalApril 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."July 13, 2022 | finance.yahoo.comPluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture SurgeryMay 10, 2022 | apnews.comPluristem: Fiscal Q3 Earnings SnapshotMarch 28, 2022 | finance.yahoo.comPluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New PartnershipMarch 23, 2022 | seekingalpha.comPluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trialMarch 23, 2022 | finance.yahoo.comPluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood TransfusionsMarch 21, 2022 | nasdaq.comPluristem Therapeutics, Inc. Common Stock (PSTI)March 8, 2022 | finance.yahoo.comPluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint VentureFebruary 24, 2022 | finance.yahoo.comPluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food PlatformJanuary 12, 2022 | marketwatch.comThinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?January 10, 2022 | msn.comIsrael's Tnuva partners with Pluristem to develop cultured cell-based meatJanuary 10, 2022 | finance.yahoo.comBiotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food PlatformJanuary 10, 2022 | nasdaq.comPluristem Climbs On Collaboration With Tnuva Of Israel For Commercialization Of Alternative MeatJanuary 10, 2022 | seekingalpha.comPluristem jumps 31% on collaboration with Tnuva to develop cultured cell-based food productsJanuary 10, 2022 | finance.yahoo.comBiotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food PlatformDecember 30, 2021 | nasdaq.comPluristem Therapeutics Inc Shares Fall 3.3% Below Previous 52-Week Low - Market MoverDecember 29, 2021 | marketwatch.comPluristem Therapeutics Shares Tumble on Covid-19 Study Failure >PSTIDecember 28, 2021 | finance.yahoo.comPluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDSDecember 27, 2021 | nasdaq.comPluristem: Phase II Studies Of ARDS Associated With COVID-19 Fails To Meet Primary Efficacy EndpointSee More Headlines Receive PSTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pluristem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today4/24/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PSTI CUSIPN/A CIK1158780 Webwww.pluristem.com Phone972747107171Fax972-74-710-8787Employees153Year Founded2003Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,870,000.00 Net MarginsN/A Pretax Margin-20,024.79% Return on Equity-100.63% Return on Assets-55.46% Debt Debt-to-Equity Ratio0.57 Current Ratio8.22 Quick Ratio8.22 Sales & Book Value Annual Sales$20,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.80 per share Price / BookN/AMiscellaneous Outstanding Shares32,348,000Free Float30,601,000Market Cap$32.35 million OptionableOptionable Beta1.91 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Yaacov Yanay (Age 51)Pres, CEO & Director Comp: $612.6kMs. Chen Franco-Yehuda (Age 38)CFO, Treasurer & Sec. Comp: $330.3kMr. Lior RavivChief Technology OfficerMs. Efrat Livne-HadassVP of HRDr. Nitsan Halevy M.D.Chief Medical OfficerMr. Nimrod Bar ZviChief Commercial OfficerMore ExecutivesKey CompetitorsCASI PharmaceuticalsNASDAQ:CASICortexymeNASDAQ:CRTXIN8bioNASDAQ:INABAchilles TherapeuticsNASDAQ:ACHLProtara TherapeuticsNASDAQ:TARAView All Competitors PSTI Stock Analysis - Frequently Asked Questions How were Pluristem Therapeutics' earnings last quarter? Pluristem Therapeutics Inc. (NASDAQ:PSTI) announced its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.41) by $0.05. When did Pluristem Therapeutics' stock split? Pluristem Therapeutics shares reverse split on the morning of Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Pluristem Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pluristem Therapeutics investors own include Teva Pharmaceutical Industries (TEVA), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Micron Technology (MU), Pfizer (PFE), SCYNEXIS (SCYX) and Advanced Micro Devices (AMD). This page (NASDAQ:PSTI) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss RatingsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluristem Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.